There are great companies, and there are companies that do great things in the marketplace…and for your health.
The latter is the kind of company I'm talking about here.
And it's the reason why its stock has soared and will continue to soar as the years roll on….
Twenty Years of Coverage Helped Me Isolate This Pick
This isn't a story I just came upon while running my screens one night. I've been following developments involving multiple sclerosis (MS) therapies for more than 20 years. It all goes back to a four-part series I wrote while working as a biotech analyst at the Oakland Tribune.
My series focused on the release of Betaseron, a genetically altered protein designed to lessen the number and severity of MS attacks.
This was in the early days of the biotech revolution, which has not only spawned some of the greatest medical discoveries but some of the greatest wealth-creating opportunities.
This drug had plenty of critics who complained about serious side effects like insomnia and depression.
However, it also was the first FDA-approved drug found to alter the course of this debilitating autoimmune disease – one known to cause severe inflammation that can impact walking, vision, and speech. It can severely shorten its victims' life expectancy as well as their ability to enjoy their remaining years.
Approved in 1993, the drug is still on the market today and is sold by a unit of Bayer AG (OTCMKTS ADR: BAYRY). It ranks as the interferon, a human protein, with the longest record of clinical effectiveness and safety.
But in recent years, there's another biotech leader that has helped revolutionize MS treatment. So much so that its portfolio of approved MS drugs has become a major catalyst driving the stock up 632% in the past five years.
What's more, this very same biotech – one of the first to emerge in the 1970s – is now focusing its attention on another insidious and even more pervasive disease: Alzheimer's.
The company also has a number of well-regarded drugs in the marketplace that have helped patients with B-cell non-Hodgkin's lymphoma, rheumatoid arthritis, chronic lymphocytic leukemia, and hemophilia.
A Company on the Move
I'm talking about Biogen Inc. (Nasdaq: BIIB), a global big-cap player that operates at the forefront of life sciences as though it were still a small, clinical-stage firm.
Consider that earlier this year the company announced it was partnering with Google Inc. (Nasdaq: GOOG, GOOGL). Biogen and Google's futuristic X labs are using sensors, software, and data analysis tools to explore why MS progresses differently in each patient.
Earlier, Biogen had initiated a project with Fitbit, using the company's activity trackers to gather data on MS patients. The Google partnership is an extension of that kind of thinking – using sensors to track the real-time medical data and also analyze all the Big Data to look for clues in treating and getting ahead of MS.
This digital health approach also has huge implications for understanding all sorts of complex diseases, from cancer to Parkinson's. It highlights the kind of creative partnering that has made Biogen such a force in the industry.
And as you can see from the continued advance in Biogen's stock, the focus on innovation is richly rewarding the company's investors.
It's Not Too Expensive and Here's Why
About the Author
Michael A. Robinson is one of the top financial analysts working today. His book "Overdrawn: The Bailout of American Savings" was a prescient look at the anatomy of the nation's S&L crisis, long before the word "bailout" became part of our daily lexicon. He's a Pulitzer Prize-nominated writer and reporter, lauded by the Columbia Journalism Review for his aggressive style. His 30-year track record as a leading tech analyst has garnered him rave reviews, too. Today he is the editor of the monthly tech investing newsletter Nova-X Report as well as Radical Technology Profits, where he covers truly radical technologies – ones that have the power to sweep across the globe and change the very fabric of our lives – and profit opportunities they give rise to. He also explores "what's next" in the tech investing world at Strategic Tech Investor.